Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy?

Japanese Journal of Clinical Oncology

Volumn 41, Issue 4, 2011, Pages 565-570

  Yuge, Kazuyuki ^a   Kikuchi, Eiji ^a   Matsumoto, Kazuhiro ^a   Takeda, Toshikazu ^a   Miyajima, Akira ^a   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Age; Bacille Calmette Gu rin; Intravesical immunotherapy; Non muscle invasive bladder cancer; Side effect

Indexed keywords

BCG VACCINE;

ADULT; AGE DISTRIBUTION; ARTICLE; BLADDER CANCER; CANCER PREVENTION; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; CYSTITIS; DRUG EFFECT; DRUG FEVER; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FEMALE; HEMATURIA; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; NONMUSCLE INVASIVE BLADDER CANCER; RECURRENCE RISK;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANALYSIS OF VARIANCE; BCG VACCINE; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MUSCLE TISSUE; PROPORTIONAL HAZARDS MODELS; URINARY BLADDER NEOPLASMS;

EID: 79953730598     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq241     Document Type: Article

References (22)

1. Prout GR, Jr, Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer 2005;104:1638-47.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-5.
4. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90-5.
5. Vazquez-Lavista LG, Flores-Balcazar CH, Llorente L. The bacillus Calmette-Guérin as immunomodulator in bladder cancer. Rev Invest Clin 2007;59:146-52.
6. Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high-risk bladder cancer. Semin Oncol 2007;34:165-72.
7. Palou J, Rodriguez-Villamil L, Andreu-Crespo A, Salvador-Bayarri J, Vicente-Rodriguez J. Intravesical treatment of severe bacillus Calmette-Guérin cystitis. Int Urol Nephrol 2001;33:485-9.
8. Suzuki S, Shinohara N, Harabayashi T, Taniguchi A, Haga K, Sato S, et al. Complications of bacillus Calmette-Guérin therapy in superficial urothelial cancer: clinical analysis and implications. Int J Clin Oncol 2002;7:289-93.
9. Takeda T, Kikuchi E, Yuge K, Matsumoto K, Miyajima A, Nakagawa K, et al. Discontinuance of bacille Calmette-Guérin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence. Urology 2009;73:1318-22.
10. Goodwin JS, Samet JM, Key CR, Humble C, Kutvirt D, Hunt C. Stage at diagnosis of cancer varies with the age of the patient. J Am Geriatr Soc 1986;34:20-6.
11. Solana R, Pawelec G, Tarazona R. Aging and innate immunity. Immunity 2006;24:491-4.
12. Chakravarti B, Abraham GN. Aging and T-cell-mediated immunity. Mech Ageing Dev 1999;108:183-206.
13. Sebastian C, Espia M, Serra M, Celada A, Lloberas J. MacrophAging: a cellular and molecular review. Immunobiology 2005;210:121-6.
14. Whisler RL, Beiqing L, Chen M. Age-related decreases in IL-2 production by human T cells are associated with impaired activation of nuclear transcriptional factors AP-1 and NF-AT. Cell Immunol 1996;169:185-95.
15. Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993;150:1018-23.
16. Joudi FN, Smith BJ, O'Donnell MA, Konety BR. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 2006;175:1634-9.
17. Herr HW. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy. Urology 2007;70:65-8.
18. Mulders PF, Meyden AP, Doesburg WH, Oosterhof GO, Debruyne FM. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group. Br J Urol 1994;73:403-8.
19. Yossepowitch O, Eggener SE, Bochner BH, Donat SM, Herr HW, Dalbagni G. Safety and efficacy of intravesical bacillus Calmette - Guérin instillations in steroid treated and immunocompromised patients. J Urol 2006;176:482-5.
20. Palou J, Angerri O, Segarra J, Caparros J, Guirado L, Diaz JM, et al. Intravesical bacillus Calmette-Guérin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation 2003;76:1514-6.
21. Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006;175:2004-10.
22. Heiner JG, Terris MK. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy. Urol Oncol 2008;26:137-40.